An Update on Caffeine Therapy
|
|
- Clemence Bridges
- 5 years ago
- Views:
Transcription
1 An Update on Caffeine Therapy Emory University School of Medicine Atlanta, GA Wally Carlo, MD University of Alabama at Birmingham Department of Pediatrics Division of Neonatology
2 Objectives Learn which neonates may benefit from methylxanthines therapy Learn the short and long-term effect of methylxanthine therapy in neonates Review the evidence for early and high dose treatment with methylxanthines
3 Is severe apnea a problem in preemies despite the currently recommended doses of methylxanthines? Is severe apnea a problem in INTUBATED preemies despite currently recommended doses of methylxanthines?
4 Pharmacokinetics of Theophylline and Caffeine Theophylline Caffeine Half life (hr) Range (hr) Loading dose (mg/kg) Maintenance (mg/kg) 1 q 8 hr 2.5 q 24 hr *Active base But there are substantial interindividual variability in PK, and monitoring plasma levels is recommended. Lopes and Aranda. Pharmacologic Treatment of Neonatal Apnea. Yaffe and Aranda (eds) 2005
5 Effect of Theophylline on Apnea with Orally Administered Theophylline Apnea/day Apnea Requiring Ventilation (N) Pre Theophylline Post Theophylline 0 Pre Theophylline Post Theophylline Uauy et al. Pediatrics 55:595, 1975
6 Effect of Caffeine on Apnea Apnea/Day p< Aranda et al. J Pediatr 90:467, Pre Caffeine With Caffeine
7 Effectiveness of Theophylline vs Caffeine Apnea Frequency 100/min Theophylline Caffeine Days
8 Methylxanthine Treatment for Apnea of Prematurity Outcome Any methylxanthine vs control Apnea Use of mechanical ventilation Theophylline vs control Apnea Use of mechanical ventilation Caffeine vs control Apnea Use of mechanical ventilation RR (95% Cl) Modified from Henderson-Smart DJ and Steer P. Cochrane Collaboration 2001.
9 Caffeine vs. Theophyline Advantages of caffeine: Longer half life, less frequency dosing (q 24 hr) Less side effects (tachycardia, feeding intolerance) Advantages of theophylline: More bronchodilator effect
10 Meta-analysis Caffeine vs. Theophylline in Preterm Apnea Tachycardia/feed intol 3% in caffeine vs 31% in theophylline (p<0.05) Apnea at days (range ) less apnea per day in theophylline group (p<0.05) Steer and Henderson-Smart. Cochrane 2003
11 Possible Mechanisms of Action of Methylxanthines in Neonates with Apnea 1. Increased respiratory center drive 2. Improved respiratory muscle contractions 3. Preferential activation of upper respiratory muscles 4. Decreased pulmonary resistance 5. Blockade of adenosine (a respiratory inhibitory neurotransmitter) 6. Diuresis
12 MINUTE VENTILAITON (ml/min/kg) INFANTS WITHOUT APNEA P A CO 2 (mmhg) INFANTS WITH APNEA DIFFERENCE IN SLOPE P<0.001 Modified from Gerhardt T, et al. Pediatrics 74:58, 1984
13 CO 2 Threshold (mmhg) CO 2 Threshold for Various Respiratory Muscles DIA PCA AN GG Carlo and DiFiore. J Appl Physiol 68:1041, 1990
14 Resolving RDS Predisposed to Apnea Apnea duration (sec/hr) p <.05 NS NS Day 1 Day 3 Day 7 Carlo et al. Am Rev Resp Dis 126:103, 1982 RDS Non RDS
15 Thus, infants will have an increased predisposition to apnea as: 1. RDS is resolving 2. PCO 2 decreases
16 Methylxanthine Effect on Extubation Failure RR Methylxanthine Control (95% CI) Viscardi /14 10/11 0.4(0.2,0.8)* Greenough /18 8/20 0.3(0.1,1.1) Barrington /10 2/10 1.5(0.3,7.1) Durand /23 15/28 0.4(0.2,1.1) Muro /12 6/6 0.3(0.1,0.7)* Pearlman /31 4/14 0.9(0.2,2.5) Total 27/108 45/89 0.5(0.3,0.8)* Henderson-Smart and Davis. The Cochrane Library 2002
17 However, 1 / 3 to ¼ of infants with apnea fail methylxanthine therapy and need intubation
18
19 Why is a Predisposition to Apnea Not Noticed to be a Problem in Infants on a Ventilator? 1. The babies have respiratory distress 2. Apnea/hypoventilation are interpreted as inability to compensate for their respiratory disease 3. A high hypercapnia threshold is interpreted as hypercapnia due to severe RDS 4. The problem is being treated!
20 Consequence of Increased Apnea as RDS Resolves 1. Many infants remain on ventilator when RDS is resolving 2. Many infants with RDS fail extubation attempts 3. Many infants may get lung injury because of being on a ventilator 4. Many infants may get a PDA ligation in part because of being on a ventilator
21 Caffeine RCT: Caffeine 5 mg/kg/day for Apnea/Extubation Patients: <10 days in 35 Centers Results: Caffeine Placebo OR (CI) p value BPD 36% 47% 0.64 (0.52, 0.78) <0.001 Death 5.2% 5.5% 0.96 (0.64, 1.44) NS Surg for PDA 4.5% 12.6% 0.29 (0.20, 0.43) <0.001 Drug for PDA 29% 38% 0.67 (0.54, 0.82) <0.001 IVH/PVL/Other 13% 14% 0.97 (0.74, 1.28) NS Less weight gain first three weeks. No difference by 4-6 weeks. Schmidt et al. NEJM 354:20, 2006
22 Caffeine RCT: 2 Year Outcomes Caffeine Placebo OR (CI) p value Death or disability 40% 46% 0.77 ( ) Death 6.4% 6.5% 0.97 ( ) NS CP 4.4% 7.3% 0.58 ( ) MDI < 85 34% 38% 0.81 ( ) 0.04 Severe retinopathy 5.1% 7.9% 0.61 ( ) 0.01 Medium wt percentile (-3.22,2.05) NS No difference in head circumference or height Schmidt et al. NEJM 357:1893, 2007
23 Caffeine RCT: 5 Year Outcomes Caffeine Placebo OR (CI) P value Death or disability 21% 25% 0.86 ( ) NS Death 6.8% 6.9% 1.03 ( ) NS No difference in growth Schmidt et al. JAMA 307:275, 2012
24 Is earlier caffeine better than later caffeine?
25 Early Caffeine Observational Study 62,000 VLBW infants treated with caffeine Early Caffeine Infants (days 1-2 of age): Lower BPD or death (27.6% vs 34.0%) p<0.001 Lower PDA (12.3% vs 19.0%) p<0.001 Lower late-onset sepsis (21.2% vs 24.5%) p<0.001 Lower mechanical ventilation (11 d vs 17 d) p<0.001 Dobson NR et al. J Peds 164:1244, 2014
26 Early Caffeine Intervention Observational Study 5101 < 31 week infants, 29 Canadian National Network centers Early-First 2 days Late-After 2 days p value BW, median (IQR) 1070 ( ) 1050 ( ) 0.66 GA, median (IQR) 28 (28-29) 28 (26-30) 0.07 Ventilation day 2 46% 58% <0.01 BPD 27.8% 27.7% NS Lodha A et al. JAMA Pediatrics 169:33, 2015
27 Thus, earlier day 1-2 caffeine treatment may be better than later treatment but these data are from respective studies prone to bias.
28 Caffeine to Reduce Intermittent Hypoxemic Episodes 98 infants of week at birth randomized to caffeine/placebo at 33 wks There was a reduction of oxygen desaturations at 35 and 36 weeks but not later. Rhine L et al. JAMA 168:250, 2014
29 Methylxanthines are very effective in preventing ventilation but is high-dose methylxanthine strategy better than a standard dose strategy?
30 Infants Responding (%) High Dose Theophylline on Apnea Response 3 up to 7.5 Theophylline maintenance dose (mg/kg/day) Muttitt et al. J Pediatr 112:115, 1988
31 Effect of Aminophylline/Theophylline 100 on Apnea Treatment Success % Success Dose kg/day
32 RCT of High-Dose Caffeine Design: Multicenter RCT (placebo) Patient population: Inclusion criteria: GA < 30 weeks and expected to be on a ventilator for > 48 hours Exclusion criteria (any of the following): major congenital anomaly, sepsis, major neurological condition, IVH 3 or 4 Intervention: Load of 80 vs 20 mg/kg/day and maintenance of 20 vs 5 mg/kg/day caffeine citrate IV or OG Planned enrollment: 222 infants, 50% reduction from 32% to 16% Primary outcome: failure of extubation within 48 hours after the loading dose
33 RCT of High-Dose Caffeine: Patient Population: N=234 infants 20 mg/kg (n=113) 5 mg/kg (n=121) Gestational age (wks) 27 ± ± 1.4 Birthweight (g) 1009 ± ± 240 Male sex 49% 52% Less than 24 weeks GA 56% 47% Antenatal steroids 86% 88% RDS 85% 91% Exogenous surfactant 80% 84% Age at enrollment (days) 4.0 (1.9-12) 3.9 (2.0-11) Mech vent at enrollment (days) 4.7 (2.5-13) 4.2 ( ) Steer et al. Arch Dis Child Fetal Neonatal Ed 89:F499, 2004
34 RCT of High-Dose Caffeine: Results 20 mg/kg (n=113) 5 mg/kg (n=121) RR (95% Cl) p value NNT Extubation failure 15% 30% 0.51 ( ) < Extubation failure <28 wks 17% 49% 0.36 (0.20, 0.65) < Duration vent < 28 wks days days <0.001 Steer et al. Arch Dis Child Fetal Neonatal Ed 89:F499, 2004
35 RCT of High-Dose Caffeine: Adverse Effects 20 mg/kg (n=113) 5 mg/kg (n=121) p value Tachycardia (HR>200) 4% 1% -- Jitteriness 2% 2% -- Caffeine withheld 8% 4% 0.24 Feed intolerance 35% 31% 0.44 Weight gain (g/kg/day) 12.2 ( ) 12.6 ( ) 0.35 Steer et al. Arch Dis Child Fetal Neonatal Ed 89:F499, 2004
36 RCT of High Dose Caffeine: Morbidity and Death 20 mg/kg (n=113) 5 mg/kg (n=121) RR (95% Cl) p value Proven infection 46% 50% 0.93 (0.71 to 1.21) 0.59 NEC 0% 4% IVH 3 or 4 5% 1% 0.11 PVL/cysts/PH H 7% 11% 0.64 (0.26 to 1.61) 0.34 ROP 3 and 4 3% 8% 0.42 (0.11 to 1.52) 0.22 Pulmonary air leak 4% 6% 0.77 (0.25 to 2.35) 0.64 BPD (36 wks) 34% 48% 0.72 (0.51 to 1.01) 0.06 Death before discharge 4% 6% 0.77 (0.25 to 2.34) 0.64 Steer et al. Arch Dis Child Fetal Neonatal Ed 89:F499, 2004
37 RCT of High Dose Caffeine: Outcomes at 12 Months Corrected for Prematurity 20 mg/kg (n=87) Dev assessment n=80 n=78 5 mg/kg (n=86) RR (95% Cl) p value General quotient (GQ) 96.6 (13.2) 92.2 (17.3) 0.08 Major disability (0.17 to 1.05) Death up to 12 months 7 8 Death or disability (0.32 to 1.08) Steer et al. Arch Dis Child Fetal Neonatal Ed 89:F499,
38 Should caffeine levels be monitored before or during a high-dose trial? Pharmacokinetic study of 5 and 20 mg/kg dosage with 431 samples in 110 infants, GA 27 weeks, BW 1.0 kg Clearance (Cl) increased nonlinearly with PNA up to 6 weeks Volume of distribution (Vd) increased linearly with weight Mean elimination half life was 101 hours Inter-individual variability of Cl was 19% Inter-occasion variability of Cl was 33% Caffeine was completely absorbed (thus same IV and enteral dosage) Thus, routine serum caffeine concentration monitoring in these patients is not warranted Steer PA and Caffeine Collaborative Study Group. Ther Drug Monit 30; 709, 2008
39 Treatment High-dose Caffeine RCT High-dose Caffeine (N=60) Usual-dose Caffeine (n=60) p value Extubation failure <0.05 Apnea frequency <0.001 Days of apnea <0.001 Mohammed S. Eur J Pediatr 2015
40 Prophylactic (day 1) High-dose Caffeine RCT Neuroimaging Results High-dose caffeine (n=37) Standard-dose caffeine (n=37) P value Cerebellar hemorrhage 36% 10% 0.03 Intraventricular hemorrhage % 11% >0.99 Periventricular leukomalacia 8% 5% 0.78 White matter injury 7% 14% 0.75 Death or cerebellar hemorrhage 49% 23% 0.03 Bayley III MDI 86% 88% 0.42 Bayley III PDI 85% 86% 0.86 McPherson CM et al. Pediatric Res 2015
41
42 Conclusion Take Home Message 1. Methylxanthine treatment has important short term benefits (less BPD, less PDA ligation, less ventilator days) 2. Currently recommended doses of methylxanthines are substantially lower than doses found to be most effective 3. High dose methylxanthines treatment is safe as evidenced by trends for improved neurologic development at follow-up but further research is needed 4. It is unclear if earlier caffeine is superior to the usual timing of initiation of caffeine
43 Caffeine - The Silver Bullet in Neonatology (Jack Aranda) Standard of care Apnea of prematurity Extubation of ventilated babies Post-operative apnea prevention Non-intended benefit. Reduction in BPD PDA ROP Cerebral palsy, Cognitive impairment Save Money NO EFFECT ON IVH or NEC
44 NIH/FDA Apnea of Prematurity Group Recently, a panel convened by the NIH and FDA reported the summary proceedings of the Apnea of Prematurity Group. The group recommended that a large (3000 patient) randomized trial powered to assess long term outcomes should be performed in preterm infants with apnea. Finer NN et al. Pediatrics 117:S47-51, 2006
45 THANKS! Prem Fort, MD Pankaj Jain, MD Jegen Kandasamy, MD Erin Mack, MD Viswanathan Prabhu, MD Colm Travers, MD Aaron Yee, MD Namasivayam Ambalavanan, MD Carl Coghill, MD Reed Dimmitt, MD, MSPH George El Ferzli, MD Hannah Hightower, MD Tamas Jilling, MD Virginia Karle, MD Joe Philips, MD Vivek Lal, MD Maran Ramani, MD Brian Sims, MD, PhD Elaine St. John, MD Trent Tipple, MD Rune Toms, MD Lindy Winter, MD
Hazards and Benefits of Postnatal Steroids. David J. Burchfield, MD Professor and Chief, Neonatology University of Florida
Hazards and Benefits of Postnatal Steroids David J. Burchfield, MD Professor and Chief, Neonatology University of Florida Disclosures I have no financial affiliations or relationships to disclose. I will
More informationNoah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018
Postnatal Steroids Use for Bronchopulmonary Dysplasia in 2018 + = Noah Hillman M.D. IPOKRaTES Conference Guadalajaira, Mexico August 23, 2018 AAP Policy Statement - 2002 This statement is intended for
More informationObjectives. Apnea Definition and Pitfalls. Pathophysiology of Apnea. Apnea of Prematurity and hypoxemia episodes 5/18/2015
Apnea of Prematurity and hypoxemia episodes Deepak Jain MD Care of Sick Newborn Conference May 2015 Objectives Differentiating between apnea and hypoxemia episodes. Pathophysiology Diagnosis of apnea and
More informationRango de saturacion de oxigeno: Cual es la evidencia?
Rango de saturacion de oxigeno: Cual es la evidencia? Wally Carlo, M.D. University of Alabama at Birmingham Department of Pediatrics Division of Neonatology wcarlo@peds.uab.edu 1 2 Stevie Wonder 4 Objectives
More informationProphylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm Neonates
Iran Red Crescent Med J. 2014 August; 16(8): e12559. Published online 2014 August 5. DOI: 10.5812/ircmj.12559 Research Article Prophylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm
More informationKugelman A, Riskin A, Said W, Shoris I, Mor F, Bader D.
Heated, Humidified High-Flow Nasal Cannula (HHHFNC) vs. Nasal Intermittent Positive Pressure Ventilation (NIPPV) for the Primary Treatment of RDS, A Randomized, Controlled, Prospective, Pilot Study Kugelman
More informationResearch Article Timing of Caffeine Therapy and Neonatal Outcomes in Preterm Infants: A Retrospective Study
International Pediatrics Volume 2016, Article ID 9478204, 6 pages http://dx.doi.org/10.1155/2016/9478204 Research Article Timing of Caffeine Therapy and Neonatal Outcomes in Preterm Infants: A Retrospective
More informationPatent Ductus Arteriosus: Philosophy or Pathology?
Patent Ductus Arteriosus: Philosophy or Pathology? Disclosure Ray Sato, MD is a speaker for Prolacta Biosciences, Inc. This presentation will discuss off-label uses of acetaminophen and ibuprofen. RAY
More informationBenefits of Caffeine Citrate: Neurodevelopmental Outcomes of ELBW Infants
St. Catherine University SOPHIA Master of Arts in Nursing Theses Nursing 12-2011 Benefits of Caffeine Citrate: Neurodevelopmental Outcomes of ELBW Infants Teri Johnson St. Catherine University Follow this
More informationCOMPARISON OF THE EFFICIENCY OF CAFFEINE VERSUS AMINOPHYLLINE FOR THE TREATMENT OF APNOEA OF PREMATURITY
CASE STUDIES COMPARISON OF THE EFFICIENCY OF CAFFEINE VERSUS AMINOPHYLLINE FOR THE TREATMENT OF APNOEA OF PREMATURITY Gabriela Ildiko Zonda 1, Andreea Avasiloaiei 1, Mihaela Moscalu 2, Maria Stamatin 1
More informationSTOP ROP The STOP-ROP Multicenter Study Group: Pediatrics 105:295, 2000 Progression to Threshold Conventional Sat 89-94% STOP ROP
Hrs TcPO2 > 80 nnhg (weeks 1 4) OXYGEN TARGETS: HOW GOOD ARE WE IN ACHIEVING THEM Oxygen Dependency GA wks Eduardo Bancalari MD University of Miami Miller School of Medicine Jackson Memorial Medical Center
More informationRespiratory Management and Outcome of Preterm Infants
Respiratory Management and Outcome of Preterm Infants 6 th Annual Care Of The Sick Newborn Conference Shu Wu, MD. Department of Pediatrics Division of Neonatology University of Miami School of Medicine
More informationUpdate on mangement of patent ductus arteriosus in preterm infants. Dr. Trinh Thi Thu Ha
Update on mangement of patent ductus arteriosus in preterm infants Dr. Trinh Thi Thu Ha Outline 1. Overview of PDA 2. Timing of screening PDA? 3. When to treat PDA? Timing of ductal closure Prenatal
More informationBubble CPAP for Respiratory Distress Syndrome in Preterm Infants
R E S E A R C H P A P E R Bubble CPAP for Respiratory Distress Syndrome in Preterm Infants JAGDISH KOTI*, SRINIVAS MURKI, PRAMOD GADDAM, ANUPAMA REDDY AND M DASARADHA RAMI REDDY From Fernandez Hospital
More informationAn Overview of Bronchopulmonary Dysplasia and Chronic Lung Disease in Infancy
An Overview of Bronchopulmonary Dysplasia and Chronic Lung Disease in Infancy Housekeeping: I have no financial disclosures Learning objectives: Develop an understanding of bronchopulmonary dysplasia (BPD)
More informationDoes Targeted Neonatal Echocardiography(TnECHO) can help prevent Postoperative Cardiorespiratory instability following PDA ligation?
Does Targeted Neonatal Echocardiography(TnECHO) can help prevent Postoperative Cardiorespiratory instability following PDA ligation? Amish Jain, Mohit Sahni, Afif El Khuffash, Arvind Sehgal, Patrick J
More informationIs There a Treatment for BPD?
Is There a Treatment for BPD? Amir Kugelman, Pediatric Pulmonary Unit and Department of Neonatology Bnai Zion Medical Center, Rappaport Faculty of Medicine Haifa, Israel Conflict of Interest Our study
More informationName and title of the investigators responsible for conducting the research: Dr Anna Lavizzari, Dr Mariarosa Colnaghi
Protocol title: Heated, Humidified High-Flow Nasal Cannula vs Nasal CPAP for Respiratory Distress Syndrome of Prematurity. Protocol identifying number: Clinical Trials.gov NCT02570217 Name and title of
More informationDisclosure COULD AUTOMATED CONTROL OF OXYGEN LEVELS IMPROVE SURVIVAL AND REDUCE NEC? Oxygen Dependency
COULD AUTOMATED CONTROL OF OXYGEN LEVELS IMPROVE SURVIVAL AND REDUCE NEC? Eduardo Bancalari MD University of Miami Miller School of Medicine Jackson Memorial Medical Center Sydney 206 Disclosure The University
More informationOriginal Policy Date
MP 8.01.17 Inhaled Nitric Oxide Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return to Medical Policy Index
More informationWhat s new in neonatal resuscitation?
What s new in neonatal resuscitation? Anup Katheria, M.D. Director, Neonatal Research Institute Sharp Mary Birch Hospital for Women & Newborns Disclosures I have no financial Disclosures. Overview Delivery
More informationPlanning Committee: Jeffery D. Horbar, MD, Madge E. Buus-Frank, RN, MS, APRN-BC, FAAN, Roger F. Soll, MD
Title of Program: What has Cochrane Neonatal Done For Babies? Speakers/Moderators: Roger F. Soll, MD Planning Committee: Jeffery D. Horbar, MD, Madge E. Buus-Frank, RN, MS, APRN-BC, FAAN, Roger F. Soll,
More informationAEROSURF Phase 2 Program Update Investor Conference Call
AEROSURF Phase 2 Program Update Investor Conference Call November 12, 2015 Forward Looking Statement To the extent that statements in this presentation are not strictly historical, including statements
More informationNon Invasive Ventilation In Preterm Infants. Manuel Sanchez Luna Hospital General Universitario Gregorio Marañón Complutense University Madrid
Non Invasive Ventilation In Preterm Infants Manuel Sanchez Luna Hospital General Universitario Gregorio Marañón Complutense University Madrid Summary Noninvasive ventilation begings in the delivery room
More informationInsults to the Developing Brain & Effect on Neurodevelopmental Outcomes
Insults to the Developing Brain & Effect on Neurodevelopmental Outcomes Ira Adams-Chapman, MD Assistant Professor of Pediatrics Director, Developmental Progress Clinic Emory University School of Medicine
More informationMethylxanthines for the Facilitation of Extubation
Open Access Original Article Prophylactic Methylxanthines for Preventing Extubation Failure in the Preterm Neonates with the Gestational Age of 30 Weeks: A Randomized Controlled Trial Shivakumar M 1, Muhammad
More informationQuality Improvement Approaches to BPD. Jay P. Goldsmith, M.D. Tulane University New Orleans, Louisiana
Quality Improvement Approaches to BPD Jay P. Goldsmith, M.D. Tulane University New Orleans, Louisiana goldsmith.jay@gmail.com No conflicts of interest to declare There is nothing more dangerous to the
More informationThe Basics. Editorial Team. Editorial Team 9/28/2017
Title of Program: What has Cochrane Neonatal Done For Babies? Speakers/Moderators: Roger F. Soll, MD Planning Committee: Jeffery D. Horbar, MD, Madge E. Buus-Frank, RN, MS, APRN-BC, FAAN, Roger F. Soll,
More informationApplication for Inclusion of Caffeine in the WHO Model List of Essential Medicines. Submitted by
Application for Inclusion of Caffeine in the WHO Model List of Essential Medicines Submitted by Clinical Pharmacology Unit Royal Children s Hospital, Melbourne, Australia Centre for International Child
More informationSAMPLE. V.12.1 Special Report: Very Low Birthweight Neonates. I. Introduction
I. Introduction V.12.1 Special Report: Very Low Birthweight Neonates The delivery of a very low birth weight infant continues to present many challenges to families and health care providers in spite of
More informationBest Practices in Bronchopulmonary
Best Practices in Bronchopulmonary Dysplasia a (BPD) Prevention e Matthew M. Laughon, MD, MPH Professor of Pediatrics The University of North Carolina at Chapel Hill I receive support from the U.S. government
More informationCPAP failure in preterm infants: incidence, predictors and consequences
CPAP failure in preterm infants: incidence, predictors and consequences SUPPLEMENTAL TEXT METHODS Study setting The Royal Hobart Hospital has an 11-bed combined Neonatal and Paediatric Intensive Care Unit
More informationAdmission/Discharge Form for Infants Born in Please DO NOT mail or fax this form to the CPQCC Data Center. This form is for internal use ONLY.
Selection Criteria Admission/Discharge Form for Infants Born in 2016 To be eligible, you MUST answer YES to at least one of the possible criteria (A-C) A. 401 1500 grams o Yes B. GA range 22 0/7 31 6/7
More informationKristi Watterberg, MD University of New Mexico
Kristi Watterberg, MD University of New Mexico Dr. Watterberg has no financial or other conflicts of interest to disclose She will be discussing studies of glucocorticoids in preterm infants History how
More informationDISCLOSURE FUNDING BRONCHOPULMONARY DYPLASIA (BPD) UCSF. Preventing BPD: Is Inhaled Nitric Oxide the Answer? March, 2009
Preventing BPD: Is Inhaled Nitric Oxide the Answer? March, 2009 Roberta A. Ballard Professor of Pediatrics UCSF DISCLOSURE INO THERAPEUTICS (IKARIA) has provided: * Inhaled Nitric Oxide (INOmax) * Delivery
More informationInformed Consent for Standard of Care Research Interventions
Informed Consent for Standard of Care Research Interventions Jeffrey R Botkin, MD, MPH Associate Vice President for Research A case Two FDA approved drugs are commonly used for the treatment of hypertension.
More informationADMISSION/DISCHARGE FORM FOR INFANTS BORN IN 2019 DO NOT mail or fax this form to the CPQCC Data Center. This form is for internal use ONLY.
1 Any eligible inborn infant who dies in the delivery room or at any other location in your hospital within 12 hours after birth and prior to admission to the NICU is defined as a "Delivery Room Death."
More informationShort-Term Outcome Of Different Treatment Modalities Of Patent Ductus Arteriosus In Preterm Infants. Five Years Experiences In Qatar
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 2 Short-Term Outcome Of Different Treatment Modalities Of Patent Ductus Arteriosus In Preterm Infants. Five Years Experiences In
More informationEvidence Summary For the Ghana Essential Medicines Committee
Evidence Summary For the Ghana Essential Medicines Committee Title: Caffeine Citrate for treating apnoea in preterm infants Formulation: 1. Injection: 20 mg/ml (equivalent to 10 mg caffeine base/ml) 2.
More informationPostnatal Steroid (PNS) Administration: Rationale
Postnatal Steroid (PNS) Administration: Rationale Background: Postnatal steroid use has been subjected to intense scrutiny in recent years, the subject of several metaanalyses and most recently been the
More informationMinimizing Lung Damage During Respiratory Support
Minimizing Lung Damage During Respiratory Support University of Miami Jackson Memorial Medical Center Care of the Sick Newborn 15 Eduardo Bancalari MD University of Miami Miller School of Medicine Jackson
More informationR espiratory distress syndrome (RDS) is generally seen in preterm infants. RDS in
Original Article Caspian J Intern Med 2018; 9(1):46-53 DOI: 10.22088/cjim.9.1.46 Fatemeh Faramarzi (PhD) 1 Mohammadreza Shiran (PhD) 2 Mohammadreza Rafati (PhD) 1* Roya Farhadi (MD) 3 Ebrahim Salehifar
More informationPEDIATRIC NEWBORN MEDICINE CLINICAL PRACTICE GUIDELINES Pharmacologic Strategies for the Prevention of Bronchopulmonary Dysplasia
PEDIATRIC NEWBORN MEDICINE CLINICAL PRACTICE GUIDELINES Pharmacologic Strategies for the Prevention of Bronchopulmonary Dysplasia Clinical Practice Guideline: Pharmacologic Strategies for the Prevention
More informationARTIFICIAL INTELLIGENCE FOR PREDICTION OF SEPSIS IN VERY LOW BIRTH WEIGHT INFANTS
ARTIFICIAL INTELLIGENCE FOR PREDICTION OF SEPSIS IN VERY LOW BIRTH WEIGHT INFANTS Markus Leskinen MD PhD, Neonatologist Children s Hospital, University of Helsinki and Helsinki University Hospital The
More informationBy: Armend Lokku Supervisor: Dr. Lucia Mirea. Maternal-Infant Care Research Center, Mount Sinai Hospital
By: Armend Lokku Supervisor: Dr. Lucia Mirea Maternal-Infant Care Research Center, Mount Sinai Hospital Background My practicum placement was at the Maternal-Infant Care Research Center (MiCare) at Mount
More informationPATENT DUCTUS ARTERIOSUS IN THE PRETERM INFANT EVIDENCE FOR & AGAINST TREATMENT
PATENT DUCTUS ARTERIOSUS IN THE PRETERM INFANT EVIDENCE FOR & AGAINST TREATMENT Dr. Youssef Abou Zanouna, FRCPI, FACC Consultant Pediatric Cardiologist King Fahd Military Medical Complex Dhahran Introduction
More informationWith wider acceptance of the early use of
Weaning of nasal CPAP in preterm infants: who, when and how? a systematic review of literature Shaili Amatya, Deepa Rastogi, Alok Bhutada, Shantanu Rastogi New York, USA Background: There is increased
More informationCaffeine and Neonatal Apnea
CAF-2012-1218-ver9-James_4P.3d 08/16/12 11:02am Page 1 JOURNAL OF CAFFEINE RESEARCH Volume 2, Number 2, 2012 ª Mary Ann Liebert, Inc. DOI: 10.1089/caf.2012.1218 Roundtable Discussion Caffeine and Neonatal
More informationSurfactant Administration
Approved by: Surfactant Administration Gail Cameron Senior Director Operations, Maternal, Neonatal & Child Health Programs Dr. Paul Byrne Medical Director, Neonatology Neonatal Policy & Procedures Manual
More informationProphylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants(review)
Cochrane Database of Systematic Reviews Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants (Review) SubramaniamP,HoJJ,DavisPG Subramaniam
More informationSaturation Targets Are They Achievable? Preventing Intermittent Hypoxemia
Saturation Targets Are They Achievable? Preventing Intermittent Hypoxemia Professor and Chief Department of Neonatology Tuebingen University Hospital Prof. Poets graduated from Hannover Medical School
More informationGS3. Understanding How to Use Statistics to Evaluate an Article. Session Summary. Session Objectives. References. Session Outline
GS3 Understanding How to Use Statistics to Evaluate an Article Reese H. Clark, MD Director of Research Pediatrix Medical Group Neonatologist Greenville Memorial Hospital, Greenville, SC The speaker has
More informationHyaline membrane disease. By : Dr. Ch Sarishma Peadiatric Pg
Hyaline membrane disease By : Dr. Ch Sarishma Peadiatric Pg Also called Respiratory distress syndrome. It occurs primarily in premature infants; its incidence is inversely related to gestational age and
More informationNEONATAL NEWS Here s Some More Good Poop
NEONATALNEWS Here ssomemoregoodpoop WINTEREDITION2010 THISNEWSLETTERISPUBLISHEDPERIODICALLYBYTHENEONATOLOGISTSOF ASSOCIATESINNEWBORNMEDICINETOCONVEYNEWANDUPDATEDPOLICIES ANDGUIDELINESANDPROVIDEGENERALEDUCATIONTONICUCARETAKERSAT
More informationEarly (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants (Review)
Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants (Review) Halliday HL, Ehrenkranz RA, Doyle LW This is a reprint of a Cochrane review, prepared and maintained
More informationBRONCHOPULMONARY DYSPLASIA
BRONCHOPULMONARY DYSPLASIA CHRONIC NEONATAL LUNG DISEASE (CLD) 2 2 nd BERLIN NEONATOLOGY SUMMER SCHOOL September 2014 3 Mt. Scopus 4 Ein Kerem 5 BRONCHOPULMONARY DYSPLASIA 1960: Ventilation of Neonates
More informationAdjusted poor weight gain for birth weight and gestational age as a predictor of severe ROP in VLBW infants
(2011) 25, 725 729 & 2011 Macmillan Publishers Limited All rights reserved 0950-222X/11 www.nature.com/eye Adjusted poor weight gain for birth weight and gestational age as a predictor of severe ROP in
More informationThe Role of Caffeine in Noninvasive Respiratory Support
The Role of Caffeine in Noninvasive Respiratory Support Nicole R. Dobson, Uniformed Serv Univ Hlth Sci Ravi Mangal Patel, Emory University Journal Title: Clinics in Perinatology Volume: Volume 43, Number
More informationReceived: Jun 15, 2013; Accepted: Nov 08, 2013; First Online Available: Jan 24, 2014
Original Article Iran J Pediatr Feb 2014; Vol 24 (No 1), Pp: 57-63 Management of Neonatal Respiratory Distress Syndrome Employing ACoRN Respiratory Sequence Protocol versus Early Nasal Continuous Positive
More informationMEDICAL POLICY I. POLICY POLICY TITLE POLICY NUMBER INHALED NITRIC OXIDE MP-4.021
Original Issue Date (Created): August 23, 2002 Most Recent Review Date (Revised): January 28, 2014 Effective Date: April 1, 2014 I. POLICY Inhaled nitric oxide may be considered medically necessary as
More informationEarly nasal intermittent positive pressure ventilation(nippv) versus early nasal continuous positive airway pressure(ncpap) for preterm
Cochrane Database of Systematic Reviews Early nasal intermittent positive pressure ventilation(nippv) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants(review) LemyreB,LaughonM,BoseC,DavisPG
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/46692 holds various files of this Leiden University dissertation Author: Zanten, Henriëtte van Title: Oxygen titration and compliance with targeting oxygen
More informationEffects of permissive hypercapnia on pulmonary and neurodevelopmental sequelae in extremely low birth weight infants: a meta analysis
DOI 10.1186/s40064-016-2437-5 REVIEW Open Access Effects of permissive hypercapnia on pulmonary and neurodevelopmental sequelae in extremely low birth weight infants: a meta analysis Jianglin Ma 1 and
More informationInfant Nutrition & Growth to Optimize Outcome Fauzia Shakeel, MD
Infant Nutrition & Growth to Optimize Outcome Fauzia Shakeel, MD Neonatologist All Children s Hospital / Johns Hopkins Medicine Affiliate Assistant Professor, University of South Florida September 2014
More informationSWISS SOCIETY OF NEONATOLOGY. Spontaneous intestinal perforation or necrotizing enterocolitis?
SWISS SOCIETY OF NEONATOLOGY Spontaneous intestinal perforation or necrotizing enterocolitis? June 2004 2 Stocker M, Berger TM, Neonatal and Pediatric Intensive Care Unit, Children s Hospital of Lucerne,
More informationThe Oxygen Controversy Why can t Neonatologists get it Correct?
The Oxygen Controversy Why can t Neonatologists get it Correct? Richard A. Polin M.D. Morgan Stanley Children s Hospital Columbia University Cyanophobia Blue Objectives To review the benefits and risks
More informationSURFACTANT UPDATE. George Mandy, M.D. Nationwide Children s Hospital The Ohio State University
SURFACTANT UPDATE George Mandy, M.D. Nationwide Children s Hospital The Ohio State University Surfactant Update Objectives History Meta-analysis of surfactant therapy New synthetic surfactant Genetic disorders
More informationA Multi center Randomized Trial of Laparotomy vs. Drainage
A Multi center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants with Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18
More informationBlood transfusion and intestinal perfusion in preterm infants Narendra Aladangady
Blood transfusion and intestinal perfusion in preterm infants Narendra Aladangady MD, FRCPCH, PhD Consultant Neonatologist Hon Clinical Professor in Child Health History of blood transfusion First report
More informationUses 1,2,3 : Labeled: Prevention of respiratory distress syndrome in premature infants
Brand Name: Surfaxin Generic Name: lucinactant Manufacturer 1 : Discovery Laboratories, Inc. Drug Class 2,3 : Synthetic lung surfactant Uses 1,2,3 : Labeled: Prevention of respiratory distress syndrome
More informationResearch Roundtable Summary
Research Roundtable Summary 10 TENTH in a Series of Seminars on MCHB-funded Research Projects Early Cortisol Deficiency and Bronchopulmonary Dysplasia October 18, 1995 Parklawn Building Potomac Conference
More informationIncidence of Bronchopulmonary Dysplasia in Korea
ORIGINAL ARTICLE Pediatrics http://dx.doi.org/1.3346/jkms.12.27.8.914 J Korean Med Sci 12; 27: 914-921 Incidence of Bronchopulmonary Dysplasia in Korea Chang Won Choi 1,2, Beyong Il Kim 1,2, Ee-Kyung Kim
More informationVon Reuss and CPAP, Disclosures CPAP. Noninvasive respiratory therapieswhy bother? Noninvasive respiratory therapies- types
Noninvasive respiratory therapiesby a nose? NEO- The Conference for Neonatology February 21, 2014 Disclosures I have no relevant financial relationships to disclose or conflicts of interest to release.
More informationDisclosures. Learning Objectives. Mechanical Ventilation of Infants with Severe BPD: An Interdisciplinary Approach 3/10/2017
Mechanical Ventilation of Infants with Severe BPD: An Interdisciplinary Approach Steven H. Abman, MD Professor, Department of Pediatrics Director, Pediatric Heart Lung Center University of Colorado School
More informationUsing histogram and event review feature on multichannel monitors to improve point of care decision making in NICU
Using histogram and event review feature on multichannel monitors to improve point of care decision making in NICU Sandesh Shivananda Associate Professor, Medical Director University of British Columbia,
More informationIs It Possible to Prevent Necrotizing Enterocolitis?
Is It Possible to Prevent Necrotizing Enterocolitis? Ravi Mangal Patel, MD MSc Associate Professor of Pediatrics Emory University School of Medicine, Atlanta, GA, USA @institutopgg @ravimpatelmd Disclosures
More informationDr Girish Deshpande, FRACP Senior Neonatologist, Department of Neonatology Nepean Hospital Sydney Senior Lecturer, University of Sydney
Dr Girish Deshpande, FRACP Senior Neonatologist, Department of Neonatology Nepean Hospital Sydney Senior Lecturer, University of Sydney Brief background Introducing probiotics in Australia Regulatory approach
More informationMcMASTER NICU INHALED STEROIDS FOR EVOLVING BPD (GA < 29 WEEKS)
McMASTER NICU INHALED STEROIDS FOR EVOLVING BPD (GA < 29 WEEKS) Developed by: Amit Mukerji, Samira Samiee-Zafarghandy, Jennifer Twiss, Ereny Bassilious, Elizabeth Vo, Shari Gray, Salhab el Helou on behalf
More informationUSE OF INHALED NITRIC OXIDE IN THE NICU East Bay Newborn Specialists Guideline Prepared by P Joe, G Dudell, A D Harlingue Revised 7/9/2014
USE OF INHALED NITRIC OXIDE IN THE NICU East Bay Newborn Specialists Guideline Prepared by P Joe, G Dudell, A D Harlingue Revised 7/9/2014 ino for Late Preterm and Term Infants with Severe PPHN Background:
More informationPredicting Mortality and Intestinal Failure in Neonates with Surgical Necrotizing Enterocolitis
Predicting Mortality and Intestinal Failure in Neonates with Surgical Necrotizing Enterocolitis Darshna Bhatt MHA DO, Curtis Travers MPH, Ravi M. Patel MD MSc, Julia Shinnick MD, Kelly Arps MD, Sarah Keene,
More informationROLE OF EARLY POSTNATAL DEXAMETHASONE IN RESPIRATORY DISTRESS SYNDROME
INDIAN PEDIATRICS VOLUME 35-FEBRUAKY 1998 ROLE OF EARLY POSTNATAL DEXAMETHASONE IN RESPIRATORY DISTRESS SYNDROME Kanya Mukhopadhyay, Praveen Kumar and Anil Narang From the Division of Neonatology, Department
More informationPrematurity as a Risk Factor for ASD. Disclaimer
Prematurity as a Risk Factor for ASD Angela M. Montgomery, MD, MSEd Assistant Professor of Pediatrics (Neonatology) Director, Yale NICU GRAD Program Suzanne L. Macari, PhD Research Scientist, Child Study
More informationObjectives. Birth Depression Management. Birth Depression Terms
Objectives Birth Depression Management Regional Perinatal Outreach Program 2016 Understand the terms and the clinical characteristics of birth depression. Be familiar with the evidence behind therapeutic
More informationA Preemie is out of the NICU Now What!? Care of the Ex Preterm Neonate
A Preemie is out of the NICU Now What!? Care of the Ex Preterm Neonate Shawn Hollinger, MD FAAP FRCPC Assistant Professor Neonatology Department of Pediatrics Adjunct Professor Obstetrics and Gynecology
More informationNasal CPAP in Neonatology: We Can Do Better
Nasal CPAP in Neonatology: We Can Do Better COI Disclosure I do not have any conflict of interest, nor will I be discussing any off-label product use. This class has no commercial support or sponsorship,
More informationEvaluation of the Local Incidence and Determinants of Bronchopulmonary Dysplasia and Pulmonary Morbidity in Extremely Preterm Infants
Evaluation of the Local Incidence and Determinants of Bronchopulmonary Dysplasia and Pulmonary Morbidity in Extremely Preterm Infants by Amber Elise Reichert A thesis submitted in partial fulfilment of
More informationPolicy #: 440 Latest Review Date: May 2016
Name of Policy: Inhaled Nitric Oxide Policy #: 440 Latest Review Date: May 2016 Category: Therapy Policy Grade: B Background/Definitions: As a general rule, benefits are payable under Blue Cross and Blue
More informationClinical Study Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm Infants
International Pediatrics Volume 2011, Article ID 783893, 7 pages doi:10.1155/2011/783893 Clinical Study Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm Infants Sandra
More information** SURFACTANT THERAPY**
** SURFACTANT THERAPY** Full Title of Guideline: Surfactant Therapy Author (include email and role): Stephen Wardle (V4) Reviewed by Dushyant Batra Consultant Neonatologist Division & Speciality: Division:
More informationProvide guidelines for the management of mechanical ventilation in infants <34 weeks gestation.
Page 1 of 5 PURPOSE: Provide guidelines for the management of mechanical ventilation in infants
More informationSteven Ringer MD PhD April 5, 2011
Steven Ringer MD PhD April 5, 2011 Disclaimer Mead Johnson sponsors programs such as this to give healthcare professionals access to scientific and educational information provided by experts. The presenter
More informationEffects of a divided high loading dose of caffeine on circulatory parameters. in preterm infants
ADC-FNN Online First, published on October 4, 2005 as 10.1136/adc.2005.073866 Effects of a divided high loading dose of caffeine on circulatory parameters in preterm infants C Hoecker 1, M Nelle 2, B Beedgen
More informationSlow versus Fast Enteral Feed Advancements in Very Low Birth Weight Infants: A Randomized Controlled Trial. A. Salhotra and S.
Original Article Slow versus Fast Enteral Feed Advancements in Very Low Birth Weight Infants: A Randomized Controlled Trial A. Salhotra and S. Ramji From the Neonatal Division, Department of Pediatrics,
More informationOutcomes From Severe ARDS Managed Without ECMO. Roy Brower, MD Johns Hopkins University Critical Care Canada Forum Toronto November 1, 2016
Outcomes From Severe ARDS Managed Without ECMO Roy Brower, MD Johns Hopkins University Critical Care Canada Forum Toronto November 1, 2016 Severe ARDS Berlin Definition 2012 P:F ratio 100 mm Hg Prevalence:
More informationSatellite Symposium. Sponsored by
Satellite Symposium Sponsored by Management of fluids and electrolytes in the preterm infant in the first week of life Pam Cairns St Michaels Hospital Bristol Healthy, term, breast fed babies Limited intake
More informationCHEST PHYSIOTHERAPY IN NICU PURPOSE POLICY STATEMENTS SITE APPLICABILITY PRACTICE LEVEL/COMPETENCIES. The role of chest physiotherapy in the NICU
PURPOSE The role of chest physiotherapy in the NICU POLICY STATEMENTS In principle chest physiotherapy should be limited to those infants considered most likely to benefit with significant respiratory
More informationChronic Lung Disease Of Prematurity. Dr Jo Harrison
Chronic Lung Disease Of Prematurity Dr Jo Harrison 9.9.14 Chronic Neonatal Lung Disease Bronchopulmonary dysplasia (BPD) first described in 1967 by Northway Defined as O 2 dependence at 28 days post birth
More informationFrom NICU to the Community. General Practitioners Study Day October 18 th 2014
From NICU to the Community General Practitioners Study Day October 18 th 2014 News in Neonatology Therapeutic hypothermia CPAP vs ventilation Palivizumab RSV prophylaxis Feeding post discharge Universal
More informationIbuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants (Review)
Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants (Review) Ohlsson A, Shah SS This is a reprint of a Cochrane review, prepared and maintained by The Cochrane
More information